AR053171A1 - N-hidroxiamidas omega-sustituidos con grupos triciclicos como inhibidores de la histona deacetilasa sus preparaciones y empleo en formulaciones farmaceuticas - Google Patents
N-hidroxiamidas omega-sustituidos con grupos triciclicos como inhibidores de la histona deacetilasa sus preparaciones y empleo en formulaciones farmaceuticasInfo
- Publication number
- AR053171A1 AR053171A1 ARP060100976A ARP060100976A AR053171A1 AR 053171 A1 AR053171 A1 AR 053171A1 AR P060100976 A ARP060100976 A AR P060100976A AR P060100976 A ARP060100976 A AR P060100976A AR 053171 A1 AR053171 A1 AR 053171A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- nconhoh
- independently
- groups
- Prior art date
Links
- 108010033040 Histones Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 abstract 2
- KWIVRAVCZJXOQC-UHFFFAOYSA-N 3h-oxathiazole Chemical compound N1SOC=C1 KWIVRAVCZJXOQC-UHFFFAOYSA-N 0.000 abstract 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 abstract 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 2
- 229930192474 thiophene Natural products 0.000 abstract 2
- -1 (CH2) m-CONR9R10 Chemical group 0.000 abstract 1
- JPWGCQPQXOHTHP-UHFFFAOYSA-N 4-(1-thiomorpholin-4-ylpiperidin-2-yl)morpholine Chemical compound O1CCN(CC1)C1N(CCCC1)N1CCSCC1 JPWGCQPQXOHTHP-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Reivindicacion 1: Compuestos de la formula general (1) en la cual X es seleccionado de: CO, CS, SO2,CH2; E es seleccionado de O, S, SO, SO2, CH2, C=O, C=CH2, N-R6, CH-OR6, CH-NR6R9, C=CH-CO-R7; A y B son independientemente seleccionados entre ciclos de 5 a 6 miembros, aromáticos como fenilo o un grupo heteroaromático seleccionado entre: furano, tiofeno, pirrol, oxazol, tiazol, imidazol, pirazol, isoxazol, isotiazol, 1,2,3-oxatiazol, 1,2,3-triazol, piridina, piridazina, pirimidina y pirazina. R1, R2, R3, R4 son independientemente seleccionados de H, halogeno, CF3, NO2, NR9R10, CN, COOH, (CH2)m-CONR9R10, C1-6 alquilo, OH, O-C1-6 alquilo, O-ciclopropilo, O-(CH2)2-O-C16 alquilo, O-(CH2)2-NR9R10, O-CONHR9, CH2-Z-R8, COR9, CR9R13R14, SR9, SOR15, SO2R15, CR9NOR9, CR9NNR9R10, un grupo Q-(CH2)nCONHOH, o bien un ciclo de 5 a 6 miembros seleccionado del grupo furano, tiofeno, pirrol, oxazol, tiazol, imidazol, pirazol, isoxazol, isotiazol, 1,2,3-oxatiazol, 1,2,3-triazol, piridina, piridazina, pirimidina, pirazina, morfolino, tiomorfolino, piperidina, pirrolidina; R5 y R6, independientemente entre ellos, pueden ser un grupo seleccionado entre: H, C1-6 alquilo, Q1-(CH2)nCONHOH, R7 s NH-(CH2)nCONHOH; R8 es (CH2)p-R11, donde R11 puede ser metilo o un hidroxilo; Z es seleccionado de O, NR12, S; Q puede ser una union química, o bien puede ser seleccionado de: -O-, -S-, -NR12, -NR9CO-, -CONR9, -W-, -COW-, bien W representa un grupo seleccionad entre piperidin o pirrolidino; Q1 puede ser una union o bien un -CO-; R9 y R10 independientemente entre ellos pueden ser H o bien C1-6 alquilo; R12 es H o R8; R13 y R14 pueden ser uno de ellos o bien ambos un átomo de F o átomo de O entre ellos vinculados por una cadena alquílica constituida por 2 o 3 grupos CH2, R15 es C1-6 alquilo; n es un numero entero incluido entre 2 y 9; m es un numero entero incluido entre 0 y 2; p es un numero entero incluido entre 0 y 5; con las siguientes limitaciones: los grupos que contienen un hidroxamato del tipo (CH2)nCONHOH, solo debe estar siempre presente en la molécula cuando X = CO, y los sustituyentes A y B representan ambos un grupo bencénico, entonces R3 y R4 no pueden ser el grupo Q-(CH2)nCONHOH. Y todos los posibles isomeros opticos, como en enantiomeros y/o diastereoisomeros, así como racémicos en relaciones distintas entre ellos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000042 IT1362675B (it) | 2005-03-15 | 2005-03-15 | N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053171A1 true AR053171A1 (es) | 2007-04-25 |
Family
ID=36676439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100976A AR053171A1 (es) | 2005-03-15 | 2006-03-14 | N-hidroxiamidas omega-sustituidos con grupos triciclicos como inhibidores de la histona deacetilasa sus preparaciones y empleo en formulaciones farmaceuticas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20080275023A1 (es) |
| EP (1) | EP1863776A1 (es) |
| JP (1) | JP2008533088A (es) |
| KR (1) | KR20080003336A (es) |
| CN (1) | CN101142197A (es) |
| AP (1) | AP2007004170A0 (es) |
| AR (1) | AR053171A1 (es) |
| AU (1) | AU2006222883A1 (es) |
| BR (1) | BRPI0608549A2 (es) |
| CA (1) | CA2600521A1 (es) |
| CO (1) | CO6321131A2 (es) |
| EA (1) | EA013015B1 (es) |
| IL (1) | IL185879A0 (es) |
| IT (1) | IT1362675B (es) |
| MA (1) | MA29673B1 (es) |
| MX (1) | MX2007011071A (es) |
| NI (1) | NI200700222A (es) |
| NO (1) | NO20075229L (es) |
| SA (1) | SA06270133B1 (es) |
| TW (1) | TW200719900A (es) |
| WO (1) | WO2006097449A1 (es) |
| ZA (1) | ZA200708754B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0523040D0 (en) * | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
| AU2013205135B2 (en) * | 2006-10-28 | 2015-11-05 | Forum Pharmaceuticals Inc. | Inhibitors of histone deacetylase |
| WO2008055068A2 (en) * | 2006-10-28 | 2008-05-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| CN101605788A (zh) * | 2006-12-11 | 2009-12-16 | 默克公司 | 用作铃蟾肽受体亚型-3调节剂的取代的二氮杂磺酰胺类化合物 |
| JP2011102240A (ja) * | 2008-02-29 | 2011-05-26 | Univ Of Tokyo | 三環性化合物 |
| US8202989B2 (en) | 2009-01-12 | 2012-06-19 | Council Of Scientific And Industrial Research | One step process for the preparation of substituted 5, 10-dihydrodibenzo [b,e][1, 4]diazepine-11-ones |
| AU2011239537A1 (en) * | 2010-04-16 | 2012-11-15 | Curis, Inc. | Treatment of cancers having K-ras mutations |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| RU2519546C1 (ru) * | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
| EP2958565A4 (en) | 2013-02-19 | 2016-07-27 | Icahn School Med Mount Sinai | TRICYCLIC HETEROCYCLES AS ANTICANCER AGENTS |
| JP2017512766A (ja) | 2014-03-11 | 2017-05-25 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗癌剤としてのトリシクリル−２−アミノシクロアルカノール由来スルホンアミド |
| US9937180B2 (en) | 2014-03-11 | 2018-04-10 | Icahn School Of Medicine At Mount Sinai | Constrained tricyclic sulfonamides |
| JP2017535573A (ja) * | 2014-11-25 | 2017-11-30 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたピリドベンゾジアゼピノン誘導体およびそれの使用 |
| WO2016089830A1 (en) | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
| WO2016089797A1 (en) | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
| WO2016089833A1 (en) | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
| GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
| US20180339985A1 (en) | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
| GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
| WO2017044571A1 (en) * | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Tricyclic sultam sulfonamides as anticancer and neuroprotective agents |
| JP6955485B2 (ja) | 2015-09-09 | 2021-10-27 | アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
| JP6966425B2 (ja) | 2015-09-09 | 2021-11-17 | アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai | 抗がん剤としての複素環式の限定された三環系スルホンアミド |
| CN105806973B (zh) * | 2016-03-10 | 2019-01-18 | 中国医学科学院肿瘤医院 | Uplc-ms/ms法测定人血浆中莎巴比星及其代谢产物m3的血药浓度 |
| US11759450B2 (en) | 2018-02-06 | 2023-09-19 | The Board Of Trustees Of The University Of Illinois | Substituted benzothiophene analogs as selective estrogen receptor degraders |
| KR102301274B1 (ko) * | 2019-08-05 | 2021-09-14 | 리퓨어생명과학 주식회사 | 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물 |
| KR102243465B1 (ko) * | 2019-08-05 | 2021-04-22 | 리퓨어생명과학 주식회사 | 히스톤 아세틸트렌스퍼라제 p300 억제용 신규 화합물 및 이를 포함하는 항섬유화 조성물 |
| WO2023020416A1 (zh) * | 2021-08-16 | 2023-02-23 | 勤浩医药（苏州）有限公司 | 三环化合物、包含其的药物组合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6033110B2 (ja) * | 1977-09-12 | 1985-08-01 | 帝国臓器製薬株式会社 | ジベンズアゼピン誘導体 |
| JPS53121780A (en) * | 1977-04-01 | 1978-10-24 | Teikoku Hormone Mfg Co Ltd | Dibenzazepin derivatives and process for their preparation |
| AR035455A1 (es) * | 2001-04-23 | 2004-05-26 | Hoffmann La Roche | Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos |
| WO2004058715A1 (ja) * | 2002-12-25 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | ジアミン誘導体 |
-
2005
- 2005-03-15 IT IT000042 patent/IT1362675B/it active
-
2006
- 2006-03-07 TW TW095107553A patent/TW200719900A/zh unknown
- 2006-03-13 EP EP06708743A patent/EP1863776A1/en not_active Withdrawn
- 2006-03-13 AU AU2006222883A patent/AU2006222883A1/en not_active Abandoned
- 2006-03-13 CA CA002600521A patent/CA2600521A1/en not_active Abandoned
- 2006-03-13 MX MX2007011071A patent/MX2007011071A/es not_active Application Discontinuation
- 2006-03-13 AP AP2007004170A patent/AP2007004170A0/xx unknown
- 2006-03-13 EA EA200701969A patent/EA013015B1/ru unknown
- 2006-03-13 US US11/886,168 patent/US20080275023A1/en not_active Abandoned
- 2006-03-13 KR KR1020077023278A patent/KR20080003336A/ko not_active Withdrawn
- 2006-03-13 BR BRPI0608549-0A patent/BRPI0608549A2/pt not_active IP Right Cessation
- 2006-03-13 WO PCT/EP2006/060661 patent/WO2006097449A1/en not_active Ceased
- 2006-03-13 CN CNA2006800082490A patent/CN101142197A/zh active Pending
- 2006-03-13 JP JP2008501283A patent/JP2008533088A/ja active Pending
- 2006-03-14 AR ARP060100976A patent/AR053171A1/es not_active Application Discontinuation
- 2006-05-08 SA SA06270133A patent/SA06270133B1/ar unknown
-
2007
- 2007-08-23 NI NI200700222A patent/NI200700222A/es unknown
- 2007-09-10 IL IL185879A patent/IL185879A0/en unknown
- 2007-10-11 MA MA30292A patent/MA29673B1/fr unknown
- 2007-10-12 CO CO07107398A patent/CO6321131A2/es not_active Application Discontinuation
- 2007-10-12 NO NO20075229A patent/NO20075229L/no not_active Application Discontinuation
- 2007-10-12 ZA ZA200708754A patent/ZA200708754B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1863776A1 (en) | 2007-12-12 |
| EA200701969A1 (ru) | 2008-02-28 |
| MX2007011071A (es) | 2007-10-08 |
| BRPI0608549A2 (pt) | 2010-01-12 |
| TW200719900A (en) | 2007-06-01 |
| NI200700222A (es) | 2008-07-24 |
| CA2600521A1 (en) | 2006-09-21 |
| ITFI20050042A1 (it) | 2006-09-16 |
| EA013015B1 (ru) | 2010-02-26 |
| NO20075229L (no) | 2007-11-08 |
| MA29673B1 (fr) | 2008-08-01 |
| AP2007004170A0 (en) | 2007-10-31 |
| WO2006097449A1 (en) | 2006-09-21 |
| SA06270133B1 (ar) | 2009-05-16 |
| KR20080003336A (ko) | 2008-01-07 |
| IL185879A0 (en) | 2008-01-06 |
| US20080275023A1 (en) | 2008-11-06 |
| CO6321131A2 (es) | 2011-09-20 |
| CN101142197A (zh) | 2008-03-12 |
| JP2008533088A (ja) | 2008-08-21 |
| ZA200708754B (en) | 2008-10-29 |
| IT1362675B (it) | 2009-06-25 |
| AU2006222883A1 (en) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053171A1 (es) | N-hidroxiamidas omega-sustituidos con grupos triciclicos como inhibidores de la histona deacetilasa sus preparaciones y empleo en formulaciones farmaceuticas | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| PE20080348A1 (es) | Moduladores tiazolopirimidina de trpv1 | |
| AR015765A1 (es) | Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento. | |
| AR040230A1 (es) | Indol, azaindol, y heterociclos relacionados de 4-alquenil piperidina | |
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
| AR061739A1 (es) | Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR047848A1 (es) | Analogos de rifamicina y composiciones farmaceuticas que los contienen. | |
| AR043059A1 (es) | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos | |
| PE20090157A1 (es) | Derivados de pirimidinona como moduladores del receptor acoplado a proteina g 119 (gpr119) | |
| DK1419773T3 (da) | 4-Phenylpiperidinderivativer som modulatorer af dopaminneurotransmission | |
| HRP20080186T3 (en) | Use of tricyclic compounds as glycine transport inhibitors | |
| DK1912979T3 (da) | Phenyl-{3-{3-(1H-pyrrol-2-YL)-[1,2,4]oxadiazol-5-YL]piperidin-1-YL}-methanon-derivater og beslægtede forbindelser som positive allosteriske modulatorer af metabotrope glutamat-receptorer | |
| AR055560A1 (es) | Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol su preparacion, composicion terapeutica y uso del compuesto para la preparacion de medicamentos | |
| PE20120657A1 (es) | Compuesto para el tratamiento de trastornos metabolicos | |
| AR076563A1 (es) | Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparacion y su apli-cacion en terapeutica | |
| PE20090549A1 (es) | Derivados de imidazolidinona con actividad sobre lxr-alfa y lxr-beta | |
| NO20090270L (no) | Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister | |
| AR049418A1 (es) | Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes. | |
| PE20050226A1 (es) | Productos aril-heteroaromaticos y composiciones que los contienen | |
| PE20070097A1 (es) | Agonistas del receptor de niacina y composiciones que contienen tales compuestos | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |